Adneuris Therapeutics Grants Exclusive License to Zhejiang Conba Pharmaceutical to Advance Cebranopadol in Greater China
Agreement Grants Conba Rights for the Development and Commercialization of Cebranopadol for Pain Across Mainland China, Hong Kong, Macao and Taiwan, representing an important step in expanding the…
Read the full articleYou might also wanna read
AstraZeneca compra a una farmacéutica de China los derechos de un medicamento pulmonar por 1.900 millones
Se trata de un inhibidor dual de PDE3/4 concebido para proporcionar efectos broncodilatadores y antiinflamatorios simultáneos.
AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical
Under the deal, Dizal is eligible to receive $600 million upfront and up to $900 million more based on clinical and sales milestones
AstraZeneca to license lung cancer drug from China’s Dizal Pharmaceutical
SHANGHAI, July 14 (Reuters) - AstraZeneca will pay Dizal Pharmaceutical $600 million upfront for global rights to one of its drugs for a typ
AstraZeneca to license lung cancer drug from China’s Dizal Pharmaceutical
SHANGHAI, July 14 (Reuters) - AstraZeneca will pay Dizal Pharmaceutical $600 million upfront for global rights to one of its drugs for a typ
China creates new regulatory pathway to accelerate access to advanced biomedical therapies
The country’s new regulatory pathway promises to accelerate access to advanced therapies for Chinese patients, but may change the licensing
biopharmadive.com·1mo ago恒瑞医药回应“双艾”组合再次延迟批准上市：未涉及产品安全性及有效性
恒瑞医药公告公司收到美国食品药品监督管理局关于注射用卡瑞利珠单抗联合甲磺酸阿帕替尼片用于不可切除或转移性肝细胞癌患者的一线治疗的生物制品许可申请的完整回复信。这也���“双艾”组合第三次被FDA延迟批准上市。对此，恒瑞医药回应称，“稳步推进国际化是公司的长期发展战略，公司多项创新
Comments
Sign in to join the conversation.
No comments yet. Be the first.